Evidence map›Paper›PMID 41679307›Full record

ArticleCell reports methods2026

An orthogonal CRISPR/Cpf1 platform for precise spatiotemporal gene regulation and osteoporotic fracture repair.

Jie Zhao, Zengliang Wang, Lina Lu, Guoyun Bu, Zukang Miao, Yang Zhang, Yue Guo, Zhao Yang, Jianxiong Ma, Jun Jiao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jie ZhaoDepartment of Orthopedic, Tianjin Hospital, Tianjin 300211, China; Tianjin Hospital, Tianjin University, Tianjin 300211, China. Electronic address: zhaojie@tmu.edu.cn.
Zengliang WangDepartment of Orthopedic, Tianjin Hospital, Tianjin 300211, China.
Lina LuTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, School of Medicine, Nankai University, Tianjin 300071, China.
Guoyun BuDepartment of Orthopedic, Tianjin Hospital, Tianjin 300211, China.
Zukang MiaoDepartment of Orthopedic, Tianjin Hospital, Tianjin 300211, China; Tianjin Hospital, Tianjin University, Tianjin 300211, China.
Yang ZhangDepartment of Orthopedic, Tianjin Hospital, Tianjin 300211, China; Tianjin Key Laboratory of Orthopedic Biomechanics and Medical Engineering, Tianjin Hospital, Tianjin 300050, China.
Yue GuoDepartment of Orthopedic, Tianjin Hospital, Tianjin 300211, China; Tianjin Key Laboratory of Orthopedic Biomechanics and Medical Engineering, Tianjin Hospital, Tianjin 300050, China.
Zhao YangDepartment of Orthopedic, Tianjin Hospital, Tianjin 300211, China.
Jianxiong MaDepartment of Orthopedic, Tianjin Hospital, Tianjin 300211, China; Tianjin Key Laboratory of Orthopedic Biomechanics and Medical Engineering, Tianjin Hospital, Tianjin 300050, China.
Jun JiaoTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, School of Medicine, Nankai University, Tianjin 300071, China. Electronic address: junjiao@nankai.edu.cn.
Xinlong MaDepartment of Orthopedic, Tianjin Hospital, Tianjin 300211, China; Tianjin Hospital, Tianjin University, Tianjin 300211, China; Tianjin Key Laboratory of Orthopedic Biomechanics and Medical Engineering, Tianjin Hospital, Tianjin 300050, China. Electronic address: maxinlong8686@yeah.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR-Cas systems enable powerful gene editing and regulation, yet single-modality control often fails to achieve orthogonal, spatiotemporally precise regulation of multiple endogenous genes. We engineered OREC, an orthogonal platform integrating chemogenetic and optogenetic modalities for precise, reversible, multiplex gene control. OREC comprises two components: OREC

Indexed as

CRISPR-Cas SystemsFracture HealingGene Expression RegulationOsteoporotic FracturesAnimalsBone Morphogenetic Protein 2ChemogeneticsDoxycyclineHumansIntercellular Signaling Peptides and ProteinsMiceOsteoblastsOsteogenesisBone Morphogenetic Protein 2Dkk1 protein, mouseDoxycyclineIntercellular Signaling Peptides and ProteinschemogeneticCP: geneticsCP: molecular biologyCRISPR/Cpf1fracture healingoptogeneticorthogonal

Identifiers

PMID41679307
PMCPMC12946740

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.